

ASX / Media Release
17 April 2014

RELEASE OF SHARES FROM VOLUNTARY ESCROW

Sydney, Thursday, 17 April 2014: OncoSil Medical Ltd (ASX: OSL) advises, in accordance with ASX Listing Rule 3.10A, that 75,000,000, ordinary shares will be released from voluntary escrow on 7 May 2014 being ten business days from today.

These shares were issued on 16 April 2013 as part of the acquisition of Enigma Therapeutics as per our announcement of that date.

ENDS

Contact:
Dr Neil Frazer
Chief Executive Officer and Managing Director
neil.frazer@oncosil.com.au
T +61 2 9223 3344
Twitter: @Dr_Neil_Frazer

About OncoSil Medical Ltd

OncoSil Medical Ltd is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical Ltd's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a bio-silica P32(phosphorous) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil™ has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumors outside of pancreatic cancer. FDA and EMA approval for pancreatic cancer is the core focus of OncoSil Medical Ltd.

Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2010 280,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 6%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn by 2015.